Hydrochlorothiazide prevents bone loss in castrated male mice.

The castration of male mice results in osteopenia which is a suitable model for evaluating the effect of thiazides on bone. The bones of castrated mice were characterized by a decrease of ash weight, bone density and calcium and phosphate bone content. When such castrated mice were treated with high dose of hydrochlorothiazide (2 mg/day/mouse) the changes in bone density and bone mineral concentration resulting from the castration were prevented. Our data indicate a beneficial effect of long-term thiazide administration on bone mineral content in male mice, which is dose dependent.

Antirenotropic action of antiandrogens cyproterone acetate, casodex, flutamide and epitestosterone.

The antirenotropic activities of three antiandrogens which are frequently used in the clinical praxis (cyproterone acetate, flutamide and casodex) and of natural endogenous antiandrogen epitestosterone were compared. The substances were administered in oil intraperitoneally to intact male mice. The weight of kidneys was decreased most effectively by casodex and epitestosterone, though the antiandrogenic activity expressed by the decreased weight of seminal vesicles was confirmed in all preparation tested, except for flutamide. Only epitestosterone significantly reduced the level of plasma testosterone, whereas casodex increased testosterone level in plasma. LH level was decreased by testosterone propionate and epitestosterone significantly, but about 50 percent increase in the mean LH level in casodex treated animals did not reach the statistical significance.

Long term administration of ascorbic acid does not improve a decreased bone weight and mineral content in rats with neonatally induced streptozotocin diabetes.

Adult female rats which were neonatally made diabetic with streptozotocin showed evidence of a pronounced decrease of dry weight, ash weight, calcium, phosphorus and ascorbic acid content in the femur, as compared with control rats. However, such diabetic rats receiving large doses of ascorbic acid (100 mg/kg/day) for 85 days did not show any improvement of the above measures in spite of normalization of bone ascorbic acid content. Thus, additional ascorbic acid given to diabetic rats with osteopenia restored bone ascorbic acid content but did not improve the bone loss resulting from chronic diabetes mellitus. Additional ascorbic acid given to intact rats did not show any additional effect on the increase of bone mass and mineral content.